Prophylactic T cell infusion after T cell- depleted bone marrow transplantation in patients with refractory lymphoma. Bone Marrow Transplant 2002; 29: 615-620.Lee CK, de Magalhaes-Silverman M, Hohl RJ et al. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in ...
Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66. PMID: 7522629.
Molecular response measured by cell-free DNA sequencing at day 7 after infusion was significantly associated with clinical response (P = 0.008), and a signature of CD8 T cell exhaustion was associated (q = 2.8 × 10−149) with a poor molecular response. Furthermore, a rare cell ...
aThe OS in all patients who received Sino 19 infusion, the median OS was 415.0 days (95% CI: 15.5–814.5). The rate of OS at 1 year was 53.0% (95% CI: 37.2–68.8).bThe OS between pediatric and adult cohort showed no significant difference (p = 0.329).cThe OS in patients ...
infusion sample [76]. It was subsequently the main source of the majority of CAR T-cells with an effector phenotype in patients [76]. As tumor cells were cleared, most CAR T-cells at the remission phase further developed into long-lived memory cells and stayed in the “resting primed” ...
After infusion, CAR T cells rapidly expanded in vivo, reaching peak concentrations after a mean of 8.6±0.8 days (median, 9 days; interquartile range, 9 to 9) (Fig. S3A). At the peak of expansion, the median number of circulating CAR T cells was 146 per microliter (interquartile rang...
transplant. The requirement of administering IL-2 after T-cell infusion in patients who participate in ACT trials may depend on the manufacturing system (with or without IL-2). It can be speculated that the effect of IL-2 during manufacturing T-cells could lead to cellular dependence on IL...
The myeloablative conditioning regimen consisted of 800 cGy total body irradiation administered in two dosages of 400 cGy within an interval of 12 hours, followed by the infusion of 5 × 106 C56BL/6 BM cells to re-establish hematopoiesis. Nonmyeloablative conditioning was performed with 10 dos...
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab Blood, 119 (26) (2012), pp. 6226-6233 CrossrefView in ScopusGoogle Scholar ...
内容提示: IMMUNOBIOLOGY AND IMMUNOTHERAPYIn vivo CAR T-cell generation in nonhuman primatesusing lentiviral vectors displaying a multidomainfusion ligandChristopher J. Nicolai, 1 Maura H. Parker, 1 Jim Qin, 1 Weiliang Tang, 1 Justin T. Ulrich-Lewis, 1 Rebecca J. Gottschalk, 1 Sara E. Cooper...